vimarsana.com

Page 14 - உயிரியல் ப்ராடக்ட்ஸ் இணை லிமிடெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WHO lists additional COVID-19 vaccine – New Business Ethiopia

The World Health Organization (WHO) today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). “The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”

The Latest: WHO validates China s Sinopharm COVID-19 vaccine for emergency use

news The Latest: WHO validates China s Sinopharm COVID-19 vaccine for emergency use Liu Qu © Provided by N.C.N. Limited  A doctor shows a box of China s Sinopharm COVID-19 vaccine in Varoslod, Hungary, Feb. 24, 2021. (Tamas Vasvari/MTI via Xinhua) WHO gave emergency use listing to Sinopharm Beijing s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, said WHO Director-General Tedros Adhanom Ghebreyesus. GENEVA, May 7 (Xinhua) The World Health Organization (WHO) validated on Friday the BBIBP-CorV COVID-19 vaccine developed by China s Sinopharm for emergency use. This afternoon, WHO gave emergency use listing to Sinopharm Beijing s COVID-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, said WHO Director-General Tedros Adhanom Ghebreyesus at a press briefing.

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations

Date Time WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG). “The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”

WHO validates China s Sinopharm Covid vaccine for emergency use

WHO validates China s Sinopharm Covid vaccine for emergency use ​ By IANS | Published on ​ Fri, May 7 2021 22:57 IST | ​ 4 Views WHO validates China s Sinopharm Covid vaccine for emergency use. Image Source: IANS News Geneva, May 7 : The World Health Organization (WHO) on Friday approved the Covid-19 vaccine developed by China s Sinopharm for emergency use. The move paves the way for the Sinopharm vaccine to be rolled out globally. This afternoon, the WHO gave emergency use listing to Sinopharm, Beijing s Covid-19 vaccine, making it the sixth vaccine to receive WHO validation for safety, efficacy and quality, WHO Director-General Tedros Ghebreyesus said during a webinar on Covid-19.

WHO approves Chinese COVID-19 vaccine for emergency use

WHO approves Chinese COVID-19 vaccine for emergency use United Nations 08 May 2021, 07:21 GMT+10 A COVID-19 vaccine produced in China has been given the green light for global rollout, potentially paving the way for its use in underserved countries, the World Health Organization (WHO) announced on Friday. The UN agency has approved the Sinopharm vaccine for emergency use, which is a prerequisite for inclusion in the global vaccine solidarity initiative, COVAX. The vaccine is easy to store, making it suitable for locations with limited resources, and proved 79 per cent effective in clinical trials. The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk , said Dr Mariângela Simao, WHO Assistant-Director General for Access to Health Products.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.